English
简体中文
Total: £ 56.28
Published Date: 2025-10-08 | Pages: 133 | Tables: 145 | Medical Care
The global Tumor-Infiltrating Lymphocyte Therapy market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Tumor-Infiltrating Lymphocyte therapy is a form of adoptive cell therapy used in cancer treatment that harnesses the patient’s own immune cells to fight tumors. TILs are a type of immune cell that naturally penetrate tumor tissues. In TIL therapy, these lymphocytes are extracted from the patient's tumor, expanded in large numbers in a laboratory, and then reintroduced into the patient after the tumor has been reduced or suppressed, typically following lymphodepleting chemotherapy.TIL therapy has shown promise particularly in the treatment of melanoma and other solid tumors.
From a downstream perspective, Melanoma accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Tumor-Infiltrating Lymphocyte Therapy leading manufacturers including Iovance Biotherapeutics, Moffitt Cancer Center, Essen Biotech, Turnstone Biologics, Obsidian Therapeutics, Hervor Therapeutics, Intima Bioscience, Instil Bio, Shanghai Juncell Therapeutics, Suzhou BlueHorse Therapeutics, etc., dominate supply; the top five capture approximately % of global revenue, with Iovance Biotherapeutics leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Tumor-Infiltrating Lymphocyte Therapy market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Iovance Biotherapeutics
Moffitt Cancer Center
Essen Biotech
Turnstone Biologics
Obsidian Therapeutics
Hervor Therapeutics
Intima Bioscience
Instil Bio
Shanghai Juncell Therapeutics
Suzhou BlueHorse Therapeutics
Grit Biotechnology
TCRCure Biopharma
BioSyngen
Sino-Cell Biomed
Segment by Type
Combined with IL-2
Not Combined with IL-2
Segment by Application
Melanoma
Cervical Cancer
Others
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Tumor-Infiltrating Lymphocyte Therapy study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Study Coverage
1.1 Introduction to Tumor-Infiltrating Lymphocyte Therapy: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Tumor-Infiltrating Lymphocyte Therapy Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Combined with IL-2
1.2.3 Not Combined with IL-2
1.3 Market Segmentation by Application
1.3.1 Global Tumor-Infiltrating Lymphocyte Therapy Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Melanoma
1.3.3 Cervical Cancer
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Tumor-Infiltrating Lymphocyte Therapy Revenue Estimates and Forecasts 2020-2031
2.2 Global Tumor-Infiltrating Lymphocyte Therapy Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Tumor-Infiltrating Lymphocyte Therapy Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Tumor-Infiltrating Lymphocyte Therapy Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Combined with IL-2 Market Size by Players
3.3.2 Not Combined with IL-2 Market Size by Players
3.4 Global Tumor-Infiltrating Lymphocyte Therapy Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Tumor-Infiltrating Lymphocyte Therapy Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Tumor-Infiltrating Lymphocyte Therapy Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Tumor-Infiltrating Lymphocyte Therapy Market Size by Type (2020-2031)
6.4 North America Tumor-Infiltrating Lymphocyte Therapy Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Tumor-Infiltrating Lymphocyte Therapy Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Tumor-Infiltrating Lymphocyte Therapy Market Size by Type (2020-2031)
7.4 Europe Tumor-Infiltrating Lymphocyte Therapy Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Tumor-Infiltrating Lymphocyte Therapy Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Tumor-Infiltrating Lymphocyte Therapy Market Size by Type (2020-2031)
8.4 Asia-Pacific Tumor-Infiltrating Lymphocyte Therapy Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Tumor-Infiltrating Lymphocyte Therapy Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Tumor-Infiltrating Lymphocyte Therapy Market Size by Type (2020-2031)
9.4 Central and South America Tumor-Infiltrating Lymphocyte Therapy Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Tumor-Infiltrating Lymphocyte Therapy Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Tumor-Infiltrating Lymphocyte Therapy Market Size by Type (2020-2031)
10.4 Middle East and Africa Tumor-Infiltrating Lymphocyte Therapy Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Tumor-Infiltrating Lymphocyte Therapy Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Iovance Biotherapeutics
11.1.1 Iovance Biotherapeutics Corporation Information
11.1.2 Iovance Biotherapeutics Business Overview
11.1.3 Iovance Biotherapeutics Tumor-Infiltrating Lymphocyte Therapy Product Features and Attributes
11.1.4 Iovance Biotherapeutics Tumor-Infiltrating Lymphocyte Therapy Revenue and Gross Margin (2020-2025)
11.1.5 Iovance Biotherapeutics Tumor-Infiltrating Lymphocyte Therapy Revenue by Product in 2024
11.1.6 Iovance Biotherapeutics Tumor-Infiltrating Lymphocyte Therapy Revenue by Application in 2024
11.1.7 Iovance Biotherapeutics Tumor-Infiltrating Lymphocyte Therapy Revenue by Geographic Area in 2024
11.1.8 Iovance Biotherapeutics Tumor-Infiltrating Lymphocyte Therapy SWOT Analysis
11.1.9 Iovance Biotherapeutics Recent Developments
11.2 Moffitt Cancer Center
11.2.1 Moffitt Cancer Center Corporation Information
11.2.2 Moffitt Cancer Center Business Overview
11.2.3 Moffitt Cancer Center Tumor-Infiltrating Lymphocyte Therapy Product Features and Attributes
11.2.4 Moffitt Cancer Center Tumor-Infiltrating Lymphocyte Therapy Revenue and Gross Margin (2020-2025)
11.2.5 Moffitt Cancer Center Tumor-Infiltrating Lymphocyte Therapy Revenue by Product in 2024
11.2.6 Moffitt Cancer Center Tumor-Infiltrating Lymphocyte Therapy Revenue by Application in 2024
11.2.7 Moffitt Cancer Center Tumor-Infiltrating Lymphocyte Therapy Revenue by Geographic Area in 2024
11.2.8 Moffitt Cancer Center Tumor-Infiltrating Lymphocyte Therapy SWOT Analysis
11.2.9 Moffitt Cancer Center Recent Developments
11.3 Essen Biotech
11.3.1 Essen Biotech Corporation Information
11.3.2 Essen Biotech Business Overview
11.3.3 Essen Biotech Tumor-Infiltrating Lymphocyte Therapy Product Features and Attributes
11.3.4 Essen Biotech Tumor-Infiltrating Lymphocyte Therapy Revenue and Gross Margin (2020-2025)
11.3.5 Essen Biotech Tumor-Infiltrating Lymphocyte Therapy Revenue by Product in 2024
11.3.6 Essen Biotech Tumor-Infiltrating Lymphocyte Therapy Revenue by Application in 2024
11.3.7 Essen Biotech Tumor-Infiltrating Lymphocyte Therapy Revenue by Geographic Area in 2024
11.3.8 Essen Biotech Tumor-Infiltrating Lymphocyte Therapy SWOT Analysis
11.3.9 Essen Biotech Recent Developments
11.4 Turnstone Biologics
11.4.1 Turnstone Biologics Corporation Information
11.4.2 Turnstone Biologics Business Overview
11.4.3 Turnstone Biologics Tumor-Infiltrating Lymphocyte Therapy Product Features and Attributes
11.4.4 Turnstone Biologics Tumor-Infiltrating Lymphocyte Therapy Revenue and Gross Margin (2020-2025)
11.4.5 Turnstone Biologics Tumor-Infiltrating Lymphocyte Therapy Revenue by Product in 2024
11.4.6 Turnstone Biologics Tumor-Infiltrating Lymphocyte Therapy Revenue by Application in 2024
11.4.7 Turnstone Biologics Tumor-Infiltrating Lymphocyte Therapy Revenue by Geographic Area in 2024
11.4.8 Turnstone Biologics Tumor-Infiltrating Lymphocyte Therapy SWOT Analysis
11.4.9 Turnstone Biologics Recent Developments
11.5 Obsidian Therapeutics
11.5.1 Obsidian Therapeutics Corporation Information
11.5.2 Obsidian Therapeutics Business Overview
11.5.3 Obsidian Therapeutics Tumor-Infiltrating Lymphocyte Therapy Product Features and Attributes
11.5.4 Obsidian Therapeutics Tumor-Infiltrating Lymphocyte Therapy Revenue and Gross Margin (2020-2025)
11.5.5 Obsidian Therapeutics Tumor-Infiltrating Lymphocyte Therapy Revenue by Product in 2024
11.5.6 Obsidian Therapeutics Tumor-Infiltrating Lymphocyte Therapy Revenue by Application in 2024
11.5.7 Obsidian Therapeutics Tumor-Infiltrating Lymphocyte Therapy Revenue by Geographic Area in 2024
11.5.8 Obsidian Therapeutics Tumor-Infiltrating Lymphocyte Therapy SWOT Analysis
11.5.9 Obsidian Therapeutics Recent Developments
11.6 Hervor Therapeutics
11.6.1 Hervor Therapeutics Corporation Information
11.6.2 Hervor Therapeutics Business Overview
11.6.3 Hervor Therapeutics Tumor-Infiltrating Lymphocyte Therapy Product Features and Attributes
11.6.4 Hervor Therapeutics Tumor-Infiltrating Lymphocyte Therapy Revenue and Gross Margin (2020-2025)
11.6.5 Hervor Therapeutics Recent Developments
11.7 Intima Bioscience
11.7.1 Intima Bioscience Corporation Information
11.7.2 Intima Bioscience Business Overview
11.7.3 Intima Bioscience Tumor-Infiltrating Lymphocyte Therapy Product Features and Attributes
11.7.4 Intima Bioscience Tumor-Infiltrating Lymphocyte Therapy Revenue and Gross Margin (2020-2025)
11.7.5 Intima Bioscience Recent Developments
11.8 Instil Bio
11.8.1 Instil Bio Corporation Information
11.8.2 Instil Bio Business Overview
11.8.3 Instil Bio Tumor-Infiltrating Lymphocyte Therapy Product Features and Attributes
11.8.4 Instil Bio Tumor-Infiltrating Lymphocyte Therapy Revenue and Gross Margin (2020-2025)
11.8.5 Instil Bio Recent Developments
11.9 Shanghai Juncell Therapeutics
11.9.1 Shanghai Juncell Therapeutics Corporation Information
11.9.2 Shanghai Juncell Therapeutics Business Overview
11.9.3 Shanghai Juncell Therapeutics Tumor-Infiltrating Lymphocyte Therapy Product Features and Attributes
11.9.4 Shanghai Juncell Therapeutics Tumor-Infiltrating Lymphocyte Therapy Revenue and Gross Margin (2020-2025)
11.9.5 Shanghai Juncell Therapeutics Recent Developments
11.10 Suzhou BlueHorse Therapeutics
11.10.1 Suzhou BlueHorse Therapeutics Corporation Information
11.10.2 Suzhou BlueHorse Therapeutics Business Overview
11.10.3 Suzhou BlueHorse Therapeutics Tumor-Infiltrating Lymphocyte Therapy Product Features and Attributes
11.10.4 Suzhou BlueHorse Therapeutics Tumor-Infiltrating Lymphocyte Therapy Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Grit Biotechnology
11.11.1 Grit Biotechnology Corporation Information
11.11.2 Grit Biotechnology Business Overview
11.11.3 Grit Biotechnology Tumor-Infiltrating Lymphocyte Therapy Product Features and Attributes
11.11.4 Grit Biotechnology Tumor-Infiltrating Lymphocyte Therapy Revenue and Gross Margin (2020-2025)
11.11.5 Grit Biotechnology Recent Developments
11.12 TCRCure Biopharma
11.12.1 TCRCure Biopharma Corporation Information
11.12.2 TCRCure Biopharma Business Overview
11.12.3 TCRCure Biopharma Tumor-Infiltrating Lymphocyte Therapy Product Features and Attributes
11.12.4 TCRCure Biopharma Tumor-Infiltrating Lymphocyte Therapy Revenue and Gross Margin (2020-2025)
11.12.5 TCRCure Biopharma Recent Developments
11.13 BioSyngen
11.13.1 BioSyngen Corporation Information
11.13.2 BioSyngen Business Overview
11.13.3 BioSyngen Tumor-Infiltrating Lymphocyte Therapy Product Features and Attributes
11.13.4 BioSyngen Tumor-Infiltrating Lymphocyte Therapy Revenue and Gross Margin (2020-2025)
11.13.5 BioSyngen Recent Developments
11.14 Sino-Cell Biomed
11.14.1 Sino-Cell Biomed Corporation Information
11.14.2 Sino-Cell Biomed Business Overview
11.14.3 Sino-Cell Biomed Tumor-Infiltrating Lymphocyte Therapy Product Features and Attributes
11.14.4 Sino-Cell Biomed Tumor-Infiltrating Lymphocyte Therapy Revenue and Gross Margin (2020-2025)
11.14.5 Sino-Cell Biomed Recent Developments
12 Tumor-Infiltrating Lymphocyte TherapyIndustry Chain Analysis
12.1 Tumor-Infiltrating Lymphocyte Therapy Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Tumor-Infiltrating Lymphocyte Therapy Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Tumor-Infiltrating Lymphocyte Therapy Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Tumor-Infiltrating Lymphocyte Therapy Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Tumor-Infiltrating Lymphocyte Therapy Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Tumor-Infiltrating Lymphocyte Therapy Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Tumor-Infiltrating Lymphocyte Therapy Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Tumor-Infiltrating Lymphocyte Therapy Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Tumor-Infiltrating Lymphocyte Therapy Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Tumor-Infiltrating Lymphocyte Therapy Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Tumor-Infiltrating Lymphocyte Therapy by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumor-Infiltrating Lymphocyte Therapy as of 2024)
Table 11. Global Tumor-Infiltrating Lymphocyte Therapy Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Tumor-Infiltrating Lymphocyte Therapy Companies Headquarters
Table 13. Global Tumor-Infiltrating Lymphocyte Therapy Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Tumor-Infiltrating Lymphocyte Therapy Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Tumor-Infiltrating Lymphocyte Therapy Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Tumor-Infiltrating Lymphocyte Therapy Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Tumor-Infiltrating Lymphocyte Therapy Revenue by Application (2026-2031) & (US$ Million)
Table 21. Tumor-Infiltrating Lymphocyte Therapy High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Tumor-Infiltrating Lymphocyte Therapy Growth Accelerators and Market Barriers
Table 25. North America Tumor-Infiltrating Lymphocyte Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Tumor-Infiltrating Lymphocyte Therapy Growth Accelerators and Market Barriers
Table 27. Europe Tumor-Infiltrating Lymphocyte Therapy Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Tumor-Infiltrating Lymphocyte Therapy Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Tumor-Infiltrating Lymphocyte Therapy Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Tumor-Infiltrating Lymphocyte Therapy Investment Opportunities and Key Challenges
Table 31. Central and South America Tumor-Infiltrating Lymphocyte Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Tumor-Infiltrating Lymphocyte Therapy Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Tumor-Infiltrating Lymphocyte Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Iovance Biotherapeutics Corporation Information
Table 35. Iovance Biotherapeutics Description and Major Businesses
Table 36. Iovance Biotherapeutics Product Features and Attributes
Table 37. Iovance Biotherapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Iovance Biotherapeutics Revenue Proportion by Product in 2024
Table 39. Iovance Biotherapeutics Revenue Proportion by Application in 2024
Table 40. Iovance Biotherapeutics Revenue Proportion by Geographic Area in 2024
Table 41. Iovance Biotherapeutics Tumor-Infiltrating Lymphocyte Therapy SWOT Analysis
Table 42. Iovance Biotherapeutics Recent Developments
Table 43. Moffitt Cancer Center Corporation Information
Table 44. Moffitt Cancer Center Description and Major Businesses
Table 45. Moffitt Cancer Center Product Features and Attributes
Table 46. Moffitt Cancer Center Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Moffitt Cancer Center Revenue Proportion by Product in 2024
Table 48. Moffitt Cancer Center Revenue Proportion by Application in 2024
Table 49. Moffitt Cancer Center Revenue Proportion by Geographic Area in 2024
Table 50. Moffitt Cancer Center Tumor-Infiltrating Lymphocyte Therapy SWOT Analysis
Table 51. Moffitt Cancer Center Recent Developments
Table 52. Essen Biotech Corporation Information
Table 53. Essen Biotech Description and Major Businesses
Table 54. Essen Biotech Product Features and Attributes
Table 55. Essen Biotech Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Essen Biotech Revenue Proportion by Product in 2024
Table 57. Essen Biotech Revenue Proportion by Application in 2024
Table 58. Essen Biotech Revenue Proportion by Geographic Area in 2024
Table 59. Essen Biotech Tumor-Infiltrating Lymphocyte Therapy SWOT Analysis
Table 60. Essen Biotech Recent Developments
Table 61. Turnstone Biologics Corporation Information
Table 62. Turnstone Biologics Description and Major Businesses
Table 63. Turnstone Biologics Product Features and Attributes
Table 64. Turnstone Biologics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Turnstone Biologics Revenue Proportion by Product in 2024
Table 66. Turnstone Biologics Revenue Proportion by Application in 2024
Table 67. Turnstone Biologics Revenue Proportion by Geographic Area in 2024
Table 68. Turnstone Biologics Tumor-Infiltrating Lymphocyte Therapy SWOT Analysis
Table 69. Turnstone Biologics Recent Developments
Table 70. Obsidian Therapeutics Corporation Information
Table 71. Obsidian Therapeutics Description and Major Businesses
Table 72. Obsidian Therapeutics Product Features and Attributes
Table 73. Obsidian Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Obsidian Therapeutics Revenue Proportion by Product in 2024
Table 75. Obsidian Therapeutics Revenue Proportion by Application in 2024
Table 76. Obsidian Therapeutics Revenue Proportion by Geographic Area in 2024
Table 77. Obsidian Therapeutics Tumor-Infiltrating Lymphocyte Therapy SWOT Analysis
Table 78. Obsidian Therapeutics Recent Developments
Table 79. Hervor Therapeutics Corporation Information
Table 80. Hervor Therapeutics Description and Major Businesses
Table 81. Hervor Therapeutics Product Features and Attributes
Table 82. Hervor Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Hervor Therapeutics Recent Developments
Table 84. Intima Bioscience Corporation Information
Table 85. Intima Bioscience Description and Major Businesses
Table 86. Intima Bioscience Product Features and Attributes
Table 87. Intima Bioscience Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Intima Bioscience Recent Developments
Table 89. Instil Bio Corporation Information
Table 90. Instil Bio Description and Major Businesses
Table 91. Instil Bio Product Features and Attributes
Table 92. Instil Bio Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Instil Bio Recent Developments
Table 94. Shanghai Juncell Therapeutics Corporation Information
Table 95. Shanghai Juncell Therapeutics Description and Major Businesses
Table 96. Shanghai Juncell Therapeutics Product Features and Attributes
Table 97. Shanghai Juncell Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Shanghai Juncell Therapeutics Recent Developments
Table 99. Suzhou BlueHorse Therapeutics Corporation Information
Table 100. Suzhou BlueHorse Therapeutics Description and Major Businesses
Table 101. Suzhou BlueHorse Therapeutics Product Features and Attributes
Table 102. Suzhou BlueHorse Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Suzhou BlueHorse Therapeutics Recent Developments
Table 104. Grit Biotechnology Corporation Information
Table 105. Grit Biotechnology Description and Major Businesses
Table 106. Grit Biotechnology Product Features and Attributes
Table 107. Grit Biotechnology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Grit Biotechnology Recent Developments
Table 109. TCRCure Biopharma Corporation Information
Table 110. TCRCure Biopharma Description and Major Businesses
Table 111. TCRCure Biopharma Product Features and Attributes
Table 112. TCRCure Biopharma Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. TCRCure Biopharma Recent Developments
Table 114. BioSyngen Corporation Information
Table 115. BioSyngen Description and Major Businesses
Table 116. BioSyngen Product Features and Attributes
Table 117. BioSyngen Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. BioSyngen Recent Developments
Table 119. Sino-Cell Biomed Corporation Information
Table 120. Sino-Cell Biomed Description and Major Businesses
Table 121. Sino-Cell Biomed Product Features and Attributes
Table 122. Sino-Cell Biomed Revenue (US$ Million) and Gross Margin (2020-2025)
Table 123. Sino-Cell Biomed Recent Developments
Table 124. Raw Materials Key Suppliers
Table 125. Distributors List
Table 126. Market Trends and Market Evolution
Table 127. Market Drivers and Opportunities
Table 128. Market Challenges, Risks, and Restraints
Table 129. Research Programs/Design for This Report
Table 130. Key Data Information from Secondary Sources
Table 131. Key Data Information from Primary Sources
List of Figures
Figure 1. Tumor-Infiltrating Lymphocyte Therapy Product Picture
Figure 2. Global Tumor-Infiltrating Lymphocyte Therapy Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Combined with IL-2 Product Picture
Figure 4. Not Combined with IL-2 Product Picture
Figure 5. Global Tumor-Infiltrating Lymphocyte Therapy Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Melanoma
Figure 7. Cervical Cancer
Figure 8. Others
Figure 9. Tumor-Infiltrating Lymphocyte Therapy Report Years Considered
Figure 10. Global Tumor-Infiltrating Lymphocyte Therapy Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global Tumor-Infiltrating Lymphocyte Therapy Revenue (2020-2031) & (US$ Million)
Figure 12. Global Tumor-Infiltrating Lymphocyte Therapy Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 13. Global Tumor-Infiltrating Lymphocyte Therapy Revenue Market Share by Region (2020-2031)
Figure 14. Global Tumor-Infiltrating Lymphocyte Therapy Revenue Market Share Ranking (2024)
Figure 15. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 16. Combined with IL-2 Revenue Market Share by Player in 2024
Figure 17. Not Combined with IL-2 Revenue Market Share by Player in 2024
Figure 18. Global Tumor-Infiltrating Lymphocyte Therapy Revenue Market Share by Type (2020-2031)
Figure 19. Global Tumor-Infiltrating Lymphocyte Therapy Revenue Market Share by Application (2020-2031)
Figure 20. North America Tumor-Infiltrating Lymphocyte Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 21. North America Top 5 Players Tumor-Infiltrating Lymphocyte Therapy Revenue (US$ Million) in 2024
Figure 22. North America Tumor-Infiltrating Lymphocyte Therapy Revenue (US$ Million) by Type (2020 - 2031)
Figure 23. North America Tumor-Infiltrating Lymphocyte Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 24. US Tumor-Infiltrating Lymphocyte Therapy Revenue (2020-2031) & (US$ Million)
Figure 25. Canada Tumor-Infiltrating Lymphocyte Therapy Revenue (2020-2031) & (US$ Million)
Figure 26. Mexico Tumor-Infiltrating Lymphocyte Therapy Revenue (2020-2031) & (US$ Million)
Figure 27. Europe Tumor-Infiltrating Lymphocyte Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 28. Europe Top 5 Players Tumor-Infiltrating Lymphocyte Therapy Revenue (US$ Million) in 2024
Figure 29. Europe Tumor-Infiltrating Lymphocyte Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 30. Europe Tumor-Infiltrating Lymphocyte Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 31. Germany Tumor-Infiltrating Lymphocyte Therapy Revenue (2020-2031) & (US$ Million)
Figure 32. France Tumor-Infiltrating Lymphocyte Therapy Revenue (2020-2031) & (US$ Million)
Figure 33. U.K. Tumor-Infiltrating Lymphocyte Therapy Revenue (2020-2031) & (US$ Million)
Figure 34. Italy Tumor-Infiltrating Lymphocyte Therapy Revenue (2020-2031) & (US$ Million)
Figure 35. Russia Tumor-Infiltrating Lymphocyte Therapy Revenue (2020-2031) & (US$ Million)
Figure 36. Asia-Pacific Tumor-Infiltrating Lymphocyte Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 37. Asia-Pacific Top 8 Players Tumor-Infiltrating Lymphocyte Therapy Revenue (US$ Million) in 2024
Figure 38. Asia-Pacific Tumor-Infiltrating Lymphocyte Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 39. Asia-Pacific Tumor-Infiltrating Lymphocyte Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 40. Indonesia Tumor-Infiltrating Lymphocyte Therapy Revenue (2020-2031) & (US$ Million)
Figure 41. Japan Tumor-Infiltrating Lymphocyte Therapy Revenue (2020-2031) & (US$ Million)
Figure 42. South Korea Tumor-Infiltrating Lymphocyte Therapy Revenue (2020-2031) & (US$ Million)
Figure 43. Australia Tumor-Infiltrating Lymphocyte Therapy Revenue (2020-2031) & (US$ Million)
Figure 44. India Tumor-Infiltrating Lymphocyte Therapy Revenue (2020-2031) & (US$ Million)
Figure 45. Indonesia Tumor-Infiltrating Lymphocyte Therapy Revenue (2020-2031) & (US$ Million)
Figure 46. Vietnam Tumor-Infiltrating Lymphocyte Therapy Revenue (2020-2031) & (US$ Million)
Figure 47. Malaysia Tumor-Infiltrating Lymphocyte Therapy Revenue (2020-2031) & (US$ Million)
Figure 48. Philippines Tumor-Infiltrating Lymphocyte Therapy Revenue (2020-2031) & (US$ Million)
Figure 49. Singapore Tumor-Infiltrating Lymphocyte Therapy Revenue (2020-2031) & (US$ Million)
Figure 50. Central and South America Tumor-Infiltrating Lymphocyte Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 51. Central and South America Top 5 Players Tumor-Infiltrating Lymphocyte Therapy Revenue (US$ Million) in 2024
Figure 52. Central and South America Tumor-Infiltrating Lymphocyte Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 53. Central and South America Tumor-Infiltrating Lymphocyte Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 54. Brazil Tumor-Infiltrating Lymphocyte Therapy Revenue (2020-2025) & (US$ Million)
Figure 55. Argentina Tumor-Infiltrating Lymphocyte Therapy Revenue (2020-2025) & (US$ Million)
Figure 56. Middle East and Africa Tumor-Infiltrating Lymphocyte Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 57. Middle East and Africa Top 5 Players Tumor-Infiltrating Lymphocyte Therapy Revenue (US$ Million) in 2024
Figure 58. South America Tumor-Infiltrating Lymphocyte Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 59. Middle East and Africa Tumor-Infiltrating Lymphocyte Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 60. GCC Countries Tumor-Infiltrating Lymphocyte Therapy Revenue (2020-2025) & (US$ Million)
Figure 61. Israel Tumor-Infiltrating Lymphocyte Therapy Revenue (2020-2025) & (US$ Million)
Figure 62. Egypt Tumor-Infiltrating Lymphocyte Therapy Revenue (2020-2025) & (US$ Million)
Figure 63. South Africa Tumor-Infiltrating Lymphocyte Therapy Revenue (2020-2025) & (US$ Million)
Figure 64. Tumor-Infiltrating Lymphocyte Therapy Industry Chain Mapping
Figure 65. Channels of Distribution (Direct Vs Distribution)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
